255 related articles for article (PubMed ID: 26136493)
1. Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation.
Gong Y; Ma Y; Sinyuk M; Loganathan S; Thompson RC; Sarkaria JN; Chen W; Lathia JD; Mobley BC; Clark SW; Wang J
Neuro Oncol; 2016 Jan; 18(1):48-57. PubMed ID: 26136493
[TBL] [Abstract][Full Text] [Related]
2. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
[TBL] [Abstract][Full Text] [Related]
3. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
4. Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors.
Chen J; Nagle AM; Wang YF; Boone DN; Lee AV
J Biol Chem; 2018 Mar; 293(10):3700-3709. PubMed ID: 29330302
[TBL] [Abstract][Full Text] [Related]
5. Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.
Chan JY; Hackel BJ; Yee D
Mol Cancer Ther; 2017 Jul; 16(7):1324-1334. PubMed ID: 28468775
[TBL] [Abstract][Full Text] [Related]
6. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
[No Abstract] [Full Text] [Related]
7. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.
Chan JY; LaPara K; Yee D
Oncogene; 2016 Aug; 35(32):4235-43. PubMed ID: 26876199
[TBL] [Abstract][Full Text] [Related]
8. Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.
Ofer P; Heidegger I; Eder IE; Schöpf B; Neuwirt H; Geley S; Klocker H; Massoner P
Mol Endocrinol; 2015 Dec; 29(12):1694-707. PubMed ID: 26452103
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of INSR/IGF1R by C-myc promotes TSCC tumorigenesis and metastasis through the NF-κB pathway.
Sun J; Lu Z; Deng Y; Wang W; He Q; Yan W; Wang A
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1873-1882. PubMed ID: 29518496
[TBL] [Abstract][Full Text] [Related]
11. Hyperactivated Insulin Signaling Cascade in Human Glioblastoma Cells.
Pei Z; Lee KC; Khan A; Wang HY
Crit Rev Oncog; 2019; 24(3):243-250. PubMed ID: 32422022
[TBL] [Abstract][Full Text] [Related]
12. Differential expression and signaling activation of insulin receptor isoforms A and B: A link between breast cancer and diabetes.
Kalla Singh S; Brito C; Tan QW; De León M; De León D
Growth Factors; 2011 Dec; 29(6):278-89. PubMed ID: 21913804
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis.
Heidegger I; Kern J; Ofer P; Klocker H; Massoner P
Oncotarget; 2014 May; 5(9):2723-35. PubMed ID: 24809298
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
15. Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells.
Sarfstein R; Nagaraj K; LeRoith D; Werner H
Cells; 2019 Nov; 8(12):. PubMed ID: 31771180
[TBL] [Abstract][Full Text] [Related]
16. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
17. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
18. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism.
Ellis BC; Graham LD; Molloy PL
Biochim Biophys Acta; 2014 Feb; 1843(2):372-86. PubMed ID: 24184209
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
Erdem C; Lee AV; Taylor DL; Lezon TR
PLoS Comput Biol; 2021 Jun; 17(6):e1009125. PubMed ID: 34191793
[TBL] [Abstract][Full Text] [Related]
20. Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.
Björner S; Rosendahl AH; Simonsson M; Markkula A; Jirström K; Borgquist S; Rose C; Ingvar C; Jernström H
Oncotarget; 2017 Feb; 8(6):9093-9107. PubMed ID: 28030849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
